MTNB earnings analysis
What we found in MTNB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied filing extract does not include income-statement, balance-sheet, cash-flow, or segment tables; the reported earnings data shows Q2 EPS of -$0.21 and revenue of $0.0. The dominant developments are the additional NYSE American noncompliance notice based on $3,022 of stockholders’ equity versus the $4,000 requirement and the October 2, 2027 compliance deadline. The proposed transactions may provide a strategic path forward, but failure to close could require substantial additional funding or a winddown, while existing stockholders are expected to retain approximately 9% ownership after completion.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Lease Dispute Resolved
- The company resolved its Bridgewater landlord litigation through a settlement effective April 7, 2026, making a $765 termination payment and exiting the premises on April 29, 2026.
- Disclosure Controls Effective
- Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026, with no material changes to internal control over financial reporting during Q2 2026.
- Strategic Transactions Announced
- Matinas entered into a Business Combination Agreement and Stock Purchase Agreement on July 10, 2026, providing potential strategic alternatives while the company seeks to address its capital and listing challenges.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- NYSE American Delisting Risk
- NYSE American issued an additional June 24, 2026 notice citing stockholders’ equity of $3,022 as of March 31, 2026, below the $4,000 requirement under Section 1003(a)(ii). The company has until October 2, 2027 to regain compliance, but failure could lead to delisting.
- Transaction Execution Risk
- The proposed Business Combination and Stock Sale are subject to shareholder approval and other closing conditions. The Business Combination Agreement may require a $1.0 million termination fee in specified circumstances if the transaction does not close.
- Funding and Dilution Risk
- If the Business Combination and Stock Sale are not completed, the company states it would need substantial additional funding and its board may pursue a winddown, dissolution or liquidation. Current stockholders are expected to own approximately 9% of Pubco Common Shares after the Business Combination, subject to adjustment.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.21
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the supplied 10-Q extract. Management states that the NYSE American granted a plan period through October 2, 2027 to regain compliance, but no operating outlook was disclosed.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 8, 2026
- Matinas BioPharma Holdings, Inc. reported a net loss of $1,921 for Q1 2026, an increase from a loss of $1,656 in Q1 2025, indicating continued financial struggles. Research and development expenditures dropped…
- 10-K · March 31, 2026
- Matinas (MTNB) is a clinical-stage biotech focused on an oral amphotericin B candidate, MAT2203, built on its LNC delivery platform. The 10-K emphasizes strong Phase 2 signals (EFA and survival) and an FDA-agreed Phase…
- 10-Q · November 10, 2025
- Matinas reported a smaller quarterly loss with net loss per share of $(0.40) for the three months ended September 30, 2025 versus $(0.85) in the year-ago quarter, driven by sharply lower R&D and overall operating…
- 10-Q · August 14, 2025
- Matinas reported no revenue for Q2 and a net loss of $5,245 (reported as $(5,245) in the filing) for the three months ended June 30, 2025, or $(1.03) per share, improving from $(5,719) and $(1.15) in the prior-year…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MTNB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever